Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.00% $24.98
America/New_York / 26 apr 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 375.42 mill |
EPS: | -1.520 |
P/E: | -16.43 |
Earnings Date: | Aug 02, 2023 |
SharesOutstanding: | 95.09 mill |
Avg Daily Volume: | 2.84 mill |
RATING 2023-04-27 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
Revenue | n/a | |||||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -16.43 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-2.80x |
Company: PE -16.43 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 24.39 - 25.57 ( +/- 2.38%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-04-27 | Sessa Capital (master), L.p. | Sell | 15 567 497 | Common Stock |
2023-04-27 | Wysenski Nancy | Sell | 128 981 | Option to Purchase Common Stock |
2023-04-27 | Wysenski Nancy | Sell | 22 200 | Option to Purchase Common Stock |
2023-04-27 | Wysenski Nancy | Sell | 23 000 | Option to Purchase Common Stock |
2023-04-27 | Wysenski Nancy | Sell | 33 000 | Option to Purchase Common Stock |
INSIDER POWER |
---|
-62.73 |
Last 100 transactions |
Buy: 11 373 023 | Sell: 48 540 195 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $24.98 (0.00% ) |
Volume | 9.12 mill |
Avg. Vol. | 2.84 mill |
% of Avg. Vol | 320.94 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.